Podcasts about mrna

The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

BUFFALO, NY – February 16, 2026 – A new #commentary was #published in Volume 17 of Oncotarget on February 6, 2026, titled “Censorship in science: How publishing decisions could have shaped the perceived “general consensus” on COVID-19 vaccine safety and efficacy.” In this commentary, led by Panagis Polykretis of the “Allineare Sanità e Salute” Foundation and the Independent Medical Scientific Commission (CMSi) in Milan, along with colleagues, the authors document a two-year effort to publish a case report and literature review that raised concerns about possible links between mRNA COVID-19 vaccines and rare blood cancers. They argue that editorial decisions, rather than scientific merit, prevented the paper from being published, raising broader questions about transparency and bias in scientific publishing. The commentary outlines the submission history of a previously written case report describing a woman who developed acute lymphoblastic leukemia shortly after receiving an mRNA COVID-19 vaccine. Alongside the case, the original paper reviewed existing studies and regulatory findings related to hematological malignancies. Despite relying on published evidence and maintaining a cautious tone, the manuscript was rejected 16 times before eventually appearing in Oncotarget. According to the authors, most journals rejected the manuscript without external peer review. Three journals allowed it to proceed through peer review, and one journal accepted the paper twice before withdrawing its decision both times. The authors argue that such cancelations, particularly after positive peer review, suggest a pattern of editorial censorship that prioritizes conformity over open scientific debate. The commentary highlights examples of reviewer feedback and editorial statements that, according to the authors, misrepresented the content of the original case report. One rejection asserted that mRNA vaccines cannot cause cancer because they do not integrate into human DNA. The authors respond that this position is overly narrow and overlooks the complex, multifactorial nature of cancer development. They also cite peer-reviewed evidence of DNA contamination in vaccine samples and call for a more balanced and open discussion of these findings. Rather than claiming definitive proof of vaccine-related harm, the authors emphasize the importance of allowing controversial topics to be examined and discussed based on evidence. They argue that suppressing disagreement, even when grounded in published science, can influence public understanding and create the appearance of scientific consensus where meaningful disagreement exists. “This case raises serious concerns: if scientifically sound dissenting research faces systematic exclusion, the resulting literature becomes selectively curated, artificially constructing ‘consensus' while marginalizing legitimate scientific discourse.” The events described in the commentary raise concerns not only about a single case report but also about broader trends in academic publishing. If journal decisions are influenced by public health messaging rather than scientific reasoning, the authors argue that the scientific literature risks becoming selectively curated. They conclude by calling for institutional reform to ensure that editorial processes remain fair, evidence-based, and open to legitimate scientific debate. DOI - https://doi.org/10.18632/oncotarget.28829 Correspondence to - Panagis Polykretis - panagis.polykretis@gmail.com Abstract video - https://www.youtube.com/watch?v=255yn3sgx-0 To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Chuck Todd takes a hard look at the state of American governance and institutional trust — or the lack of it. He starts by reflecting on the historical significance of three consecutive one-term presidents, ranking his top five most underrated commanders-in-chief and arguing that both Biden and Trump are unlikely to be viewed as consequential a century from now. From there, Todd pivots to a searing indictment of the current moment: from the Epstein reckoning exposing the government's inability to tell the truth, to DHS being treated as a political plaything by Kristi Noem and Corey Lewandowski, to the DOD endangering lives in the El Paso FAA incident with zero accountability, to Moderna alleging that HHS refused to even review an mRNA flu vaccine under RFK Jr.'s watch. He connects the dots across a pattern of institutional dishonesty — a Justice Department focused on narrative management, masked ICE agents no one can justify, a fired antitrust chief clearing the way for powerful interests, and a "hostage system" style of governing that holds federal paychecks as leverage — making the case that when the government lies this often, it forfeits the benefit of the doubt on everything, and that the Epstein scandal isn't just a story about one man, but a mirror reflecting a system designed to protect the powerful. Then, Gene Sperling — the only person to serve as Director of the National Economic Council under two presidents (Clinton and Obama), a senior advisor to President Biden who oversaw the American Rescue Plan, and a consultant and co-writer on NBC's The West Wing — joins the Chuck Toddcast for a wide-ranging conversation. Sperling shares the wild story of how he ended up in Santa Monica, his brush with Aaron Sorkin's legal troubles, and his insider take on how real Washington compares to its fictional portrayals. The conversation then turns to Sperling's deep expertise on the economy, from his defense of the Biden administration's "soft landing" amid global post-Covid inflation to the political lessons of how rising prices have sunk presidencies on both sides of the aisle — including Biden's own re-election bid. The back half of the episode looks squarely at the future. Sperling, who says he's unlikely to serve in another Democratic administration, offers a forceful argument about what comes next: the rising threat of unchecked corporate and tech power, the urgent need for AI policy that puts working people first, and the lessons of globalization that policymakers can't afford to repeat. Drawing on themes from his book Economic Dignity, he makes the case that Americans are hungry for leaders who pair optimism with a real confrontation of economic injustice — and warns that a handful of AI and crypto companies, flush with lobbying dollars, could end up shaping the structure of the economy if left unchallenged. Finally, Chuck hops into the ToddCast Time Machine to revisit the publishing of the Communist Manifesto and argues that while its critiques of the excesses of capitalism were correct… it’s revolutionary prescriptions led to the worst authoritarian states in modern history. He also answers listeners’ questions in the “Ask Chuck” segment. Get your wardrobe sorted and your gift list handled with Quince. Don't wait! Go to https://Quince.com/CHUCK for free shipping on your order and 365-day returns. Now available in Canada, too! Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/chuck. Application times may vary. Rates may vary. Thank you Wildgrain for sponsoring. Visit http://wildgrain.com/TODDCAST and use the code "TODDCAST" at checkout to receive $30 off your first box PLUS free Croissants for life! Link in bio or go to https://getsoul.com & enter code TODDCAST for 30% off your first order. Timeline: (Timestamps may vary based on advertisements) 00:00 Chuck Todd’s introduction 03:30 We’ve had 3 straight one term presidents, deem them all failures 04:45 Inability to win reelection will always be seen as an asterisk 05:45 Top 5 most underrated presidents 06:00 James Polk was the only voluntary one term president 06:45 James Garfield was a fierce advocate for civil rights 07:30 George H.W. Bush was accomplished, but not a good politician 08:30 John Quincy Adams laid out modern American infrastructure 09:00 Jimmy Carter did many things that have aged well 10:15 In 100 years, Biden & Trump likely won’t be viewed as consequential 11:45 Biden & Trump can’t be evaluated fairly for many years 12:30 What does a real reckoning look like in the Trump era? 13:45 The institution least capable of reckoning with Epstein is the government 14:15 The private sector is forcing accountability, the government isn’t 15:15 Trust is the currency of government, and Trump’s doesn’t have it 16:15 The Justice Department is only worried about narrative management 17:30 The system looks like a club, designed to protect the powerful 18:45 Epstein is a test of whether the government can tell the truth 20:00 DHS shutting down, politicians using paychecks as leverage 20:30 We a governing via a “hostage system” 21:45 There isn’t a single good argument for masking ICE agents 22:15 The Democrats’ demands are not extreme, they’re common sense 23:15 Noem & Lewandowski treating DHS like their personal plaything 24:00 Pattern of government saying one thing, facts saying another 25:15 Whatever Noem says first, you can’t believe it. She gaslights the public 26:00 The government has lied too many times, gets no benefit of the doubt 26:45 El Paso FAA incident is case study for public distrusting institutions 27:45 DoD was lying to the FAA, FAA pulled the emergency brakes 29:00 DoD put lives in danger with no accountability 29:30 Moderna says HHS refused to review MRNA flu vaccine 30:15 The U.S. is not a stable country to develop & release products 31:00 Kennedy only offers crackpot theories & totally unfit for office 32:00 We can’t trust the government to tell us the truth about anything 32:30 DOJ fired antitrust chief, powerful interests get what they want 34:00 Epstein isn’t just a scandal, it’s a mirror 43:30 Gene Sperling joins the Chuck Toddcast 45:30 The wild story of how Gene ended up in Santa Monica 46:45 Aaron Sorkin couldn’t meet with Gene due to legal trouble 49:45 Real politics/news look nothing like “West Wing” or “The Newsroom” 51:00 The one truism about the West Wing is good people trying to do good 52:45 Politics is NOT like House of Cards 54:15 West Wing still remains viable, any chance of a reboot? 55:30 What’s the state of the economy? What do you look for? 56:15 Biden economy was strong growth, but high inflation 57:00 Biden achieved the “soft landing” they were trying for 58:15 Inflation was global and mostly due to Covid supply chain shocks 59:45 The American Rescue Plan had many positive effects 1:00:45 Every head of state poured money into economies during Covid 1:01:45 Covid was going to result in either inflation or recession 1:03:30 Obama couldn’t pass enough stimulus during Great Recession 1:04:30 A little extra stimulus can help offset future unknowns 1:05:15 Millennials’ future was permanently damaged by Great Recession 1:06:30 A generation had never seen high inflation until Covid 1:07:30 Anger over inflation sunk Biden’s re-election 1:08:30 Inflation is bipartisan, took down 3 different presidents 1:09:30 Inflation affects everyone, jobs & unemployment don’t 1:10:45 Every head of state suffered politically post pandemic 1:12:45 Will Biden baggage sink Pete Buttigieg, or is that overstated? 1:14:30 Biden’s conflict was empathy for suffering vs touting achievements 1:16:45 Biden had the tiniest of margins to pass major legislation 1:18:00 Gene is unlikely to work in a future Democratic administration 1:18:45 Pitchforks are being sharpened for corporations and big tech 1:19:30 Will worker rage fuel the next election? 1:20:30 Presidents that do well offer optimism, but confront economic injustice 1:22:00 People don’t want to feel like they are being extracted for profits 1:24:00 AI growth can’t come at the expense of working people 1:25:30 AI policy should be shaped around improving conditions for people 1:26:45 What lessons from globalization can be used to alleviate AI disruption? 1:28:30 Clinton believed in robust response to globalization 1:29:30 Clinton couldn’t implement strong safety net after losing congress 1:31:15 You have to have policies where people don’t feel left behind 1:33:00 We need to create and fund jobs that create dignity 1:33:45 We need to create an economic dignity floor for all Americans 1:35:45 When is a company too big to regulate? 1:38:00 If companies are disproportionately determining policies, they’re too big 1:38:45 Crypto & AI are getting what they want from huge lobbying money 1:39:30 A handful of AI companies could determine structure of the economy 1:41:45 The Trump White House has invited corporate influence 1:49:45 What if Ro Khanna and Thomas Massie ran on “accountability” ticket 1:51:00 A bipartisan ticket of “pox on both their houses” could be powerful 1:51:45 ToddCast Time Machine February 21st, 1848 1:52:00 Marx & Engels publish the communist manifesto 1:52:45 Monarchies were colliding with modern economic forces 1:54:15 Marx argued that capitalism is destabilizing if left unchecked 1:55:15 If the manifesto was called something else, how would we view it? 1:55:45 Marx doesn’t argue reform, says that capitalism will destroy itself 1:56:30 Communist states didn’t emerge until decades after manifesto 1:57:15 Manifesto gave dictators arguments to grab power 1:58:00 Marx talked in economics, dictators exploited his language 1:59:30 Communism took hold in places where industrialization fell behind 2:00:15 Manifesto gets invoked badly by both sides in American politics 2:01:00 Marx’s diagnosis was spot on, his solutions were questionable 2:02:30 Lack of regulation for AI will push people to radicalism 2:03:00 Ask Chuck 2:03:15 Does something seem off with the administration’s economic numbers? 2:07:30 Do we need a punchier title than “Gate” for political scandals? 2:10:00 Do we need to withhold congressional salaries during shutdowns? 2:14:00 Missing intellectuals like Rahm Emmanuel leading the country 2:16:00 What is the criteria for impeachment of cabinet members? 2:18:45 Favorite football/baseball players as a kid?See omnystudio.com/listener for privacy information.

Chuck Todd takes a hard look at the state of American governance and institutional trust — or the lack of it. He starts by reflecting on the historical significance of three consecutive one-term presidents, ranking his top five most underrated commanders-in-chief and arguing that both Biden and Trump are unlikely to be viewed as consequential a century from now. From there, Todd pivots to a searing indictment of the current moment: from the Epstein reckoning exposing the government's inability to tell the truth, to DHS being treated as a political plaything by Kristi Noem and Corey Lewandowski, to the DOD endangering lives in the El Paso FAA incident with zero accountability, to Moderna alleging that HHS refused to even review an mRNA flu vaccine under RFK Jr.'s watch. He connects the dots across a pattern of institutional dishonesty — a Justice Department focused on narrative management, masked ICE agents no one can justify, a fired antitrust chief clearing the way for powerful interests, and a "hostage system" style of governing that holds federal paychecks as leverage — making the case that when the government lies this often, it forfeits the benefit of the doubt on everything, and that the Epstein scandal isn't just a story about one man, but a mirror reflecting a system designed to protect the powerful. Finally, Chuck hops into the ToddCast Time Machine to revisit the publishing of the Communist Manifesto and argues that while its critiques of the excesses of capitalism were correct… it’s revolutionary prescriptions led to the worst authoritarian states in modern history. He also answers listeners’ questions in the “Ask Chuck” segment. Get your wardrobe sorted and your gift list handled with Quince. Don't wait! Go to https://Quince.com/CHUCK for free shipping on your order and 365-day returns. Now available in Canada, too! Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/chuck. Application times may vary. Rates may vary. Thank you Wildgrain for sponsoring. Visit http://wildgrain.com/TODDCAST and use the code "TODDCAST" at checkout to receive $30 off your first box PLUS free Croissants for life! Link in bio or go to https://getsoul.com & enter code TODDCAST for 30% off your first order. Timeline: (Timestamps may vary based on advertisements) 00:00 Chuck Todd’s introduction 02:30 We’ve had 3 straight one term presidents, deem them all failures 03:45 Inability to win reelection will always be seen as an asterisk 04:45 Top 5 most underrated presidents 05:00 James Polk was the only voluntary one term president 05:45 James Garfield was a fierce advocate for civil rights 06:30 George H.W. Bush was accomplished, but not a good politician 07:30 John Quincy Adams laid out modern American infrastructure 08:00 Jimmy Carter did many things that have aged well 09:15 In 100 years, Biden & Trump likely won’t be viewed as consequential 10:45 Biden & Trump can’t be evaluated fairly for many years 11:30 What does a real reckoning look like in the Trump era? 12:45 The institution least capable of reckoning with Epstein is the government 13:15 The private sector is forcing accountability, the government isn’t 14:15 Trust is the currency of government, and Trump’s doesn’t have it 15:15 The Justice Department is only worried about narrative management 16:30 The system looks like a club, designed to protect the powerful 17:45 Epstein is a test of whether the government can tell the truth 19:00 DHS shutting down, politicians using paychecks as leverage 19:30 We a governing via a “hostage system” 20:45 There isn’t a single good argument for masking ICE agents 21:15 The Democrats’ demands are not extreme, they’re common sense 22:15 Noem & Lewandowski treating DHS like their personal plaything 23:00 Pattern of government saying one thing, facts saying another 24:15 Whatever Noem says first, you can’t believe it. She gaslights the public 25:00 The government has lied too many times, gets no benefit of the doubt 25:45 El Paso FAA incident is case study for public distrusting institutions 26:45 DoD was lying to the FAA, FAA pulled the emergency brakes 28:00 DoD put lives in danger with no accountability 28:30 Moderna says HHS refused to review MRNA flu vaccine 29:15 The U.S. is not a stable country to develop & release products 30:00 Kennedy only offers crackpot theories & totally unfit for office 31:00 We can’t trust the government to tell us the truth about anything 31:30 DOJ fired antitrust chief, powerful interests get what they want 33:00 Epstein isn’t just a scandal, it’s a mirror 42:15 What if Ro Khanna and Thomas Massie ran on “accountability” ticket 43:30 A bipartisan ticket of “pox on both their houses” could be powerful 44:15 ToddCast Time Machine February 21st, 1848 44:30 Marx & Engels publish the communist manifesto 45:15 Monarchies were colliding with modern economic forces 46:45 Marx argued that capitalism is destabilizing if left unchecked 47:45 If the manifesto was called something else, how would we view it? 48:15 Marx doesn’t argue reform, says that capitalism will destroy itself 49:00 Communist states didn’t emerge until decades after manifesto 49:45 Manifesto gave dictators arguments to grab power 50:30 Marx talked in economics, dictators exploited his language 52:00 Communism took hold in places where industrialization fell behind 52:45 Manifesto gets invoked badly by both sides in American politics 53:30 Marx’s diagnosis was spot on, his solutions were questionable 55:00 Lack of regulation for AI will push people to radicalism 55:30 Ask Chuck 55:45 Does something seem off with the administration’s economic numbers? 1:00:00 Do we need a punchier title than “Gate” for political scandals? 1:02:30 Do we need to withhold congressional salaries during shutdowns? 1:06:30 Missing intellectuals like Rahm Emmanuel leading the country 1:08:30 What is the criteria for impeachment of cabinet members? 1:11:15 Favorite football/baseball players as a kid?See omnystudio.com/listener for privacy information.

Die Corona-Pandemie mag vorbei sein, für die mRNA beginnt die Zukunft. Die Impfstoffe der nächsten Generation sollen wirksamer, zielgerichteter und besser verträglich sein. Selbst an einem Nachfolger für die Spritze wird geforscht. Von Joachim Budde www.deutschlandfunk.de, Wissenschaft im Brennpunkt

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Die Corona-Pandemie mag vorbei sein, für die mRNA beginnt die Zukunft. Die Impfstoffe der nächsten Generation sollen wirksamer, zielgerichteter und besser verträglich sein. Selbst an einem Nachfolger für die Spritze wird geforscht. Von Joachim Budde www.deutschlandfunk.de, Wissenschaft im Brennpunkt

TWiV explains the observation that filamentous virions act as non-infectious interfering particles to modulate papillomavirus infection, and transmission of monkeypox virus from fire-footed rope squirrels to sooty mangabeys. Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Positions in Rosenfeld Lab (email) FDA refuses to review Moderna flu mRNA vaccine (CIDRAP) Oz measles vaccine call, too little too late? (dw.com) Defective human papillomavirus interfering virus particles (J Virol) Fire-footed rope squirrel potential MPXV reservoir (Nature) Squirrels could be MPXV reservoir (Nature) Letters read on TWiV 1297 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Silo TV series Kathy – Ancient RNA expression profiles from the extinct woolly mammoth and Ancient host-associated microbes obtained from mammoth remains Alan – Ubik, by Philip K. Dick Vincent – Starry Messenger by Neil deGrasse Tyson Listener Pick Beth – Iceland crime fiction authors Yrsa Sigurdardottir and Ragnar Jonasson Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

"It's the Dow!" Hosts: Darren Weeks, Vicky Davis Website for the show: https://governamerica.com Vicky's website: https://thetechnocratictyranny.com COMPLETE SHOW NOTES AND CREDITS AT: https://governamerica.com/radio/radio-archives/22654-govern-america-february-14-2026-it-s-the-dow Listen LIVE every Saturday at 11AM Eastern or 8AM Pacific at http://governamerica.net or on your favorite app. FAA closes air space over border after Mexican mafia fly drones into U.S. Cartels doxx the acting ICE director, Todd Lyons, terrorizing his family. Senate targets sanctuary officials, but why make a new law when there are already unenforced laws on the books criminalizing the harboring of illegal aliens? Border czar Tom Homan draws down Minnesota surge as midterms approach. The SAVE Act sails through the House, but stalls in the Senate along with DHS funding. Bondi does Congress. A Second U.S. carrier heads to the Middle East as tensions with Iran continue to be elevated and talks falter. Suicidal tranny shoots up a school in Canada, as the pattern of trans mental illness continues its deadly rampage. In the second hour, Adam Finnegan joins us to talk about Lyme Disease and a secretive biolab that was discovered in Las Vegas, believed to have been controlled by the Chinese Communist Party. In the final hour, Mary Tocco is back to talk about vaccines, COVID, natural health, and the threat of a new pandemic.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are shocked by recent events, including Dr. Oz's appeal for measles vaccination, Vinjay Prasad's unilateral rejection of Moderna's mRNA influenza vaccine application, and the increasing number of New World screw worm cases, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, the number of measles deaths in Mexico, long COVID treatment center, where to go for answers to your long COVID questions, choroid plexus alterations in long COVID association with neuropathologies and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode How Dr. Oz's appeal to get measles vaccine may differ from RFK Jr.'s messaging (ABC News) FDA reverses course, refuses to review Moderna's application for new mRNA flu vaccine (CIDRAP) Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit (American Academy of Pediatrics: Pediatrics) US Olympic Committee remains 'dialed in' to prevent spread of stomach illness at Winter Games (CNN) Oz promotes measles vaccination (NY Times; USA Today; Fortune) Screw worm in Mexico (Gobierno de Mexico) Mexico reports more human New World screwworm infections (CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles outbreak poses risk of 'irreversible' brain damage, health officials warn (Fox News) In Mexico, at least 28 have died from measles outbreak that started 2025 (Reuters) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza vaccination and the risk of myocardial infarction(BMC Publich Health) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database (Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks (Alzheimer's & Dementia) Reaching out to US house representative Letters read on TWiV 1296 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Robert W. Malone, MD, MS, is a virologist and immunologist and an original inventor of mRNA delivery and vaccination as a technology, DNA vaccination, and multiple non-viral DNA and RNA/mRNA platform delivery technologies. He serves on the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices and is the author of multiple books, the most recent of which is “PsyWar: Enforcing the New World Order,” co-written with his wife, Dr. Jill Glasspool Malone. The Drs. Malone are the founders of the Malone Institute, which focuses on issues related to government, the biological sciences, and medicine.www.skyhorsepublishing.com/9781510782952/psywar/www.malone.newswww.malonebroadcasting.comwww.maloneinstitute.orgwww.rwmalonemd.com Perplexity: Download the app or ask Perplexity anything at https://pplx.ai/rogan. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Moderna (MRNA) experienced a wild start to 2026, with shares nearly doubling before pulling back 20% from the recent 52-week high. Rick Ducat dives into technical trends to watch and the various support and resistance levels in the stock chart. As for the options flow, Rick talks about the massively outsized move traders experienced Friday. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the US Food and Drug Administration's controversial decision to refuse to file Moderna's mRNA-1010 seasonal influenza vaccine candidate, including the unusual public airing of grievances (2:10), the changing issues sparking RTF actions (5:51), the uncertainty created by the decision and how vaccine sponsors should react going forward (16:54). More On These Topics From The Pink Sheet Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA: https://insights.citeline.com/pink-sheet/vaccines/moderna-cites-changing-advice-as-us-fda-refuses-to-file-flu-vaccine-bla-SRLIEHHMOFEWFPTLYJCXFIF5FM/ HHS Defends US FDA Refusal To File Moderna's Flu Vaccine: https://insights.citeline.com/pink-sheet/vaccines/hhs-defends-us-fda-refusal-to-file-modernas-flu-vaccine-NULTQ6P6R5C6DDXZFMZROE3HRU/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. The gang discusses why management's comments had such a profound effect on the stock. Plus, a look at Moderna after the recent FDA approval and stocks on our radar Tyler Crowe, Matt Frankel, and Jon Quast discuss: - The market's sharp reaction to Shopify's earnings - e-commerce in the era of agentic commerce - The FDA's refusal to review Moderna's new flu vaccine - Stocks on our radar Companies discussed: SHOP, AMZN, GOOG, PINS, WMT, MRNA, TREX, CROX, SAFRY Host: Tyler Crowe Guests: Matt Frankel, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

COVID Vax Causes 1100% Increase in Military Deaths, Sudden Adult Death Syndrome (SADS), Newt Gingrich Voter Fraud, The Left Calls for Revolution   1100% increase in U.S. military deaths throughout 2021, compared to 2020 COVID-19 mRNA injections can cause Sudden Adult Death Syndrome (SADS) years after injection by permanently damaging the heart Newt Gingrich- Why Honest Elections and Border Enforcement Still Matter Andrew Klavan- Why We Should Be Terrified of the Left's Call For Revolution   Post Attorney Todd Callender exposes a 1100% increase in U.S. military deaths throughout 2021, compared to 2020. "People with three shots have no immune system left over whatsoever." "There is no other way to characterize this other than intentional homicide, the unlawful taking of a human life, except that it's in large numbers, which makes it a genocide." Not A Number @myhiddenvalue   Post COVID-19 mRNA injections can cause Sudden Adult Death Syndrome (SADS) years after injection by permanently damaging the heart with lethal micro-scars. Our study is the first to fully define the syndrome known as "COVID-19 vaccine-induced cardiac arrest" Nicolas Hulscher, MPH @NicHulscher   Newt Gingrich Why Honest Elections and Border Enforcement Still Matter https://youtu.be/TqwPjdWpAX4?si=77vpOg1mI7Sx_r-W Gingrich 360 15.9K subscribers Feb 5, 2026 https://www.gingrich360.net/p/why-hon...   Post RealRobert @Real_RobN Here it is: The State of Wisconsin, Election Month November 2020. Over 200,000 illegal mail-in ballots cast in the Wisconsin 2020 election. “We were able to examine actual envelopes that contained the mail-in ballots. This allowed us to identify by person, by address, by word.” • More than 3,000 incomplete or falsified ballot certificates. • More than 2,000 had no initials. • More than 17,271 were illegally dropped off. Tens of thousands more were affected because the ballots were co-mingled. Indefinitely confined—unable to get to the polls. • More than 28,395 people identified provided no identification, including one of Joe Biden's electors. • More than 170,000 ballots were submitted without any application. In other words: Trump also won the State of Wisconsin. Now, Pass the Save Act   Why We Should Be Terrified of the Left's Call For Revolution https://youtu.be/0DRm8n5o7bw?si=_nnF7mpZsOUyRIMY Andrew Klavan 812K subscribers 45,136 views Jan 27, 2026 The Andrew Klavan Show The left thinks that America is on the verge of Hilter-ian fascism. That's clearly not true, however, it's indicative of a deeper disconnect that the left has with reality. -- -- -- LIKE & SUBSCRIBE for new videos daily.    / @andrewklavan   Click here to join the member-exclusive portion of my show: https://get.dailywire.com -- -- -- Watch the full episode here: DailyWire+: Become a Daily Wire Member and watch all of our content ad-free: https://www.dailywire.com/subscribe

America Out Loud PULSE with Malcolm Out Loud and Nicolas Hulscher – Have the vaccinated permanently damaged themselves, or are they completely beyond repair? Have you seen any signs that the mRNA can leave the body? Can the vaccine shed through intercourse or is it at a safe enough time from the vaccine that I shouldn't worry? ...

America Out Loud PULSE with Malcolm Out Loud and Nicolas Hulscher – Have the vaccinated permanently damaged themselves, or are they completely beyond repair? Have you seen any signs that the mRNA can leave the body? Can the vaccine shed through intercourse or is it at a safe enough time from the vaccine that I shouldn't worry? ...

Nine are dead in a tragic school shooting in British Columbia, Canada, Violent clashes erupt in Albania over a corruption scandal, Benjamin Netanyahu meets President Trump to discuss the Iran nuclear talks, the FAA lifts its El Paso, Texas airspace closure, Kenya's foreign minister will visit Russia over reports of a military recruitment scheme, the Colombian President's helicopter is diverted over an alleged shooting threat, a man is questioned and released in the Nancy Guthrie disappearance, the FDA rejects Moderna's mRNA flu vaccine over the trial design, the Pentagon adds ChatGPT to GenAI.mil for 3 million personnel, and Britney Spears sells the rights to her music catalog. Sources: Verity.News

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this no-holds-barred interview, Dr. Jay Bhattacharya, director of the National Institutes of Health, breaks down how the world's largest public funder of biomedical research is changing under his leadership.Bhattacharya, a former professor of Stanford University, public health expert, and coauthor of the anti-lockdown Great Barrington Declaration, was sworn in as director of the NIH in April last year.With an annual budget of almost $50 billion, the NIH sets the direction of research at universities, medical centers, and research institutes across America.It encompasses 27 institutes and centers that cover different areas of health and employ some 20,000 people. One of those is the National Institute of Allergy and Infectious Diseases, which was headed by Dr. Anthony Fauci for nearly 40 years.The NIH, Bhattacharya told me, “really hasn't had a change in leadership in decades. ... We've had new directors, but the fundamental structure and direction of the NIH has been basically the same until last year.”Bhattacharya says his top priority is to end the practice of “funding the scientific enterprise for the sake of funding science” and ensure that NIH-funded scientific research actually produces better health outcomes for the American people. The goal should be improvements in health and longevity, not just more scientific papers, he says.During our interview, we covered a lot of ground, including:-Has the NIH completely stopped funding gain-of-function research?-Is the NIH continuing to fund research with China?-How has funding for international research institutes been restructured?-Has the NIH stopped funding all research grants related to diversity, equity, and inclusion initiatives?-What is being done to reverse the politicization of science?-What is the NIH doing to help those who suffered injuries from the mandated COVID-19 mRNA vaccines?-What can the NIH do to alleviate the massive replication crisis in research?-How does he view the controversy surrounding vaccines and autism? Is the NIH looking into potential links?-How is the NIH restructuring the allocation of funding?What America needs, Bhattacharya told me, is a “second scientific revolution,” saying: “The NIH has the capacity to induce that second scientific revolution. That's what I'm going to work toward for the next few years.”Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

Howie Kurtz on the latest in the investigation into the kidnapping of Nancy Guthrie, newly released Epstein files showing President Trump reportedly contacted Palm Beach Police to support their investigation into Jeffrey Epstein, and the FDA's refusing to review Moderna's application for a new mRNA flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Tom opens this week's livestream with updates and announcements:Registration remains open for the New Biology Experience at Polyface Farm (June 2026). Tom reminds the audience there's still time to sign up and join him, the New Biology Clinic team, and community members for a weekend of talks, food, music, and connection.New Biology Experience link here.In honor of Heart Month, DrTomCowan.com is offering a Heart Health Sale on:Hibiscus Concentrate and Human Heart, Cosmic Heart book.This sale ends TONIGHT at 11:59 PM PT.This week's science news includes:-A satirical open letter to Vernon Coleman and the announcement of his nomination for the “Put-sky Gas Bag of the Year” award-A Johns Hopkins study linking hydrogen sulfide (fart gas) to Alzheimer's prevention-A claim that the shingles vaccine slows aging and dementia-Evolution “going into overdrive” exactly 66 million years ago-A new mRNA-based sickle cell “cure” priced at $3 millionA thoughtful Q&A on:-Are chemtrails real? And if so, how should we go about detoxifying from chemtrails?-Is it OK to blend foods?-Why do people get kidney stones and what can you do to prevent them?-What are warts and what is their purpose?-Is shedding real?-What about cataracts?-Somebody asked about getting a superficial fungal infection—usually in places like your groin or your armpit, or sometimes what's called athlete's foot.Support the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

AlabamaAn event involving 1819 News CEO is cancelled over threats and safetyAL House Majority Leader Scott Stadhagen to run for ALGOP ChairmanAn illegal alien is under arrest in Mobile for kidnapping of 3 peopleNew EBT cards from AL Dept of Human Resources are now chip enabledState Sales tax holiday coming for severe weather suppliesMobile pastor, Travis Johnson talks about new book and how he learned to stand up for his faithNationalA federal appeals court rules that DHS can end TPS status for migrantsPresident Trump takes on Canada for courting China and ignoring USFL Congresswoman has plans to send the SAVE Act over to Senate for voteFBI releases the warrant document leading to raid of election hub in GAAZ sheriff has person of interest in custody re: kidnapped Nancy GuthrieFDA has rejected Moderna's review request for new mRNA flu vaccine

BUFFALO, NY – February 11, 2026 – A new #casereport was published in Volume 17 of Oncotarget on February 6, 2026, titled “Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms.” In this report, led by first author Patrizia Gentilini along with corresponding author Panagis Polykretis from the “Allineare Sanità e Salute” Foundation and Independent Medical Scientific Commission (CMSi), Milano, an international team of researchers presented a detailed case involving a healthy, athletic woman who developed acute lymphoblastic leukemia and lymphoblastic lymphoma shortly after receiving her second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine. The authors reviewed existing literature and discussed possible immune-related mechanisms that could connect mRNA vaccines to blood cancers, calling attention to the need for further investigation. The case report focuses on a 38-year-old woman who began experiencing immune-related symptoms the day after her second COVID-19 mRNA vaccine dose. Within months, she was diagnosed with an aggressive blood cancer affecting early-stage lymphocytes. While she initially achieved complete remission through chemotherapy, she later experienced a central nervous system relapse and underwent a stem cell transplant. The sequence of events raises questions about whether the vaccine-induced immune response may have contributed to disease onset or progression. To provide broader context, the authors reviewed several other reports describing similar cancer cases after COVID-19 vaccination. These included lymphomas, leukemias, and other haematopoietic disorders. In many cases, symptoms appeared shortly after vaccination. While these instances remain rare, the authors argue that the patterns merit closer study. They also discuss potential mechanisms, including immune suppression, increased inflammation, and vaccine-related interference with key cancer-protective proteins such as p53. One concern highlighted in the report involves lipid nanoparticles used to deliver the vaccine, which may circulate beyond the injection site and reach organs such as the bone marrow. The authors note that changes in immune signaling, antibody responses, and genetic material could, under certain conditions, create conditions favorable to cancer development in susceptible individuals. However, they emphasize that a definitive cause-and-effect relationship has not been established. “The carcinogenic risk associated with these technologies, which has long been known within the gene therapy field, represents an area of research that cannot be ignored, given the fundamental principle of medicine “primum non nocere” (first, do no harm).” Although the case does not prove that vaccination caused the cancer, it adds to a small body of evidence suggesting that immune disturbances from mRNA vaccines should be studied further. The authors emphasize the importance of continuing long-term safety monitoring as mRNA vaccine technologies are expanded to other uses. Understanding potential rare risks is essential for ensuring informed public health decisions while maintaining trust in vaccine programs. DOI - https://doi.org/10.18632/oncotarget.28827 Correspondence to - Panagis Polykretis - panagis.polykretis@gmail.com Abstract video - https://www.youtube.com/watch?v=OO-wewH7mEY To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we delve into the dynamic landscape of these industries, exploring ambitious strategic plans, regulatory hurdles, scientific breakthroughs, and emerging trends that are shaping the future of healthcare.Let's begin with AstraZeneca, which has set an ambitious target to achieve $80 billion in revenue by 2030. This goal reflects their intention to bring over 25 blockbuster drugs to market, underscoring a commitment to innovation and expansion in their therapeutic portfolio. The focus on cutting-edge research is not just a strategy for growth but also a sign of the broader industry trend where large pharmaceutical companies pursue high-value targets to strengthen their market positions. AstraZeneca is also making strides in the weight-loss market with its new candidate elecoglipron, undergoing an extensive late-stage program to evaluate its efficacy as a monotherapy and in combination treatments for various indications. This development positions AstraZeneca competitively in the burgeoning sector, offering a novel therapeutic option for obesity management.Meanwhile, CSL Limited is undergoing a leadership transition. CEO Paul McKenzie has stepped down under pressure, and Gordon Naylor has been appointed as interim chief. This change highlights the critical role of strategic leadership in navigating industry challenges and maintaining growth trajectories amidst a rapidly shifting market landscape.In a display of financial success, Novartis reported a record-breaking performance for 2025. This achievement led to a 30% increase in CEO Vas Narasimhan's compensation, reaching $32 million. The company's robust financial health is attributed to advancing innovative treatments targeting unmet medical needs, emphasizing how achieving innovation milestones can significantly enhance corporate valuation and leadership rewards.Incyte is preparing for the patent expiration of its blood cancer drug Jakafi in 2028 by focusing on Opzelura, a topical cream that has witnessed a 33% sales increase from the previous year. With sales reaching $678 million, Opzelura's success highlights Incyte's strategic pivot to diversify its product offerings and mitigate risks associated with patent cliffs. This exemplifies how companies must continuously innovate and adapt to maintain competitive advantages.Moderna has entered into a long-term agreement with Mexico to ensure local mRNA vaccine supply through technology transfer to Laboratorios Liomont. This partnership extends Moderna's global footprint and underscores the critical role of mRNA technology in pandemic preparedness and vaccine accessibility, reinforcing its transformative impact on public health strategies.Regulatory landscapes have also seen notable activity. The FDA issued untitled letters concerning potentially misleading drug advertisements from companies like Novo Nordisk, Argenx, and Sobi. Such actions emphasize regulatory vigilance in marketing practices. Additionally, Lilly's Kinsunla failed to secure approval in Scotland, while Regenxbio faced rejection for its gene therapy for Hunter syndrome. These regulatory hurdles highlight the rigorous oversight pharma companies face and the complex pathways drugs must navigate before market approval.Collaborations within the industry are proving crucial for innovation. Merck's collaboration with Calla Lily Clinical Care aims to enhance delivery systems for vaginal therapeutics. Similarly, Bristol Myers Squibb's partnership with Evinova focuses on integrating AI into clinical development processes. These alliances reflect an industry-wide emphasis on leveraging technology to improve drug delivery efficiency and streamline clinical trial operations.Shifting our focus now to scientific advancements and clinical trial results that aSupport the show

What if the story of vaccines is really a story about protecting what we value most? We sit down with biomedical researcher Dr. Rob Balza to chart the arc from smallpox variolation to today's mRNA platforms, then push past headlines to the data that actually changes lives. Along the way, we face the hard questions Christians are asking: how do we balance stewardship of our bodies with love for immunocompromised neighbors? What does “personal choice” mean when disease spreads before symptoms? And how do we weigh decades of clinical evidence against the pull of a compelling anecdote?We break the science down clearly. Attenuated and “old school” vaccines trained the immune system with weakened pathogens; mRNA vaccines use a temporary set of instructions so your cells make a single target protein, prompting immunity without the virus itself. We unpack trial results showing early high efficacy against infection, strong and durable protection against severe disease, and shorter infectious periods that can reduce spread. We also talk openly about waning antibodies, evolving variants, and why expectations should adapt as the virus changes.Trust is the other half of the story. We examine how mixed messaging about masks, politicized guidance, and recycled myths—like the debunked vaccine-autism claim—fractured public confidence. Then we turn to a sensitive ethical concern: fetal-derived cell lines used in research. Dr. Balza explains moral proximity, timing, and intent, clarifying that vaccines don't contain fetal tissue and that long-established lines don't require new abortions. Through a Lutheran lens of vocation and providence, we explore how God often works through ordinary callings—clinicians, scientists, and citizens—to safeguard the vulnerable.Come for the history; stay for the clarity. You'll leave with a grounded understanding of how vaccines work, how evidence should be weighed, and how faith can guide wise, neighbor-loving choices in a world where our decisions ripple outward. If this resonates, subscribe, share the episode with someone who has questions, and leave a review to help others find the show.Support the showThe ministry of Christian Life Resources promotes the sanctity of life and reaches hearts with the Gospel. We invite you to learn more about the work we're doing: https://christianliferesources.com/

The p53 protein plays a central role in preventing cancer by responding to cellular stress and DNA damage. When activated, it can repair damaged DNA or trigger cell death, preventing the survival of potentially malignant cells. Loss of p53 function is a hallmark of many cancers. HPV is well known to inactivate p53 through its E6 protein, which promotes p53 degradation. This mechanism contributes to HPV-associated cancers, including cervical, anal, and head and neck cancers. SARS-CoV-2, while not traditionally classified as an oncogenic virus, has been shown to interfere with immune function and, in some cases, with cellular pathways that involve p53. A recent article by Dr. Wafik El-Deiry of The Warren Alpert Medical School of Brown University, published in Oncotarget, proposes a scientific hypothesis suggesting that proteins from HPV and SARS-CoV-2 may both interfere with the body's tumor-suppressing mechanisms, potentially compounding their effects on cancer-related pathways. The Hypothesis: HPV E6 and SARS-CoV-2 Spike Proteins May Cooperatively Suppress p53 In the paper, titled “Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53,” Dr. El-Deiry proposes that the SARS-CoV-2 spike protein, whether introduced via infection or mRNA vaccination, may suppress p53 activity in a manner that complements the effects of HPV E6. In individuals with persistent HPV infection, this combined interference could further reduce p53 function, weakening tumor suppression mechanisms. Full blog - https://www.oncotarget.org/2026/02/09/how-hpv-and-covid-19-spike-proteins-may-interact-to-impact-cancer-suppression/ Paper DOI - https://doi.org/10.18632/oncotarget.28823 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Abstract video - https://www.youtube.com/watch?v=2GJVmpG4fPk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28823 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, HPV, COVID, p53, spike To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Waardeer je onze video's? Steun dan Café Weltschmerz, het podium voor het vrije woord: https://www.cafeweltschmerz.nl/doneren/Bill Gates was in 2017 van plan pandemiesimulaties te organiseren samen met Jeffrey EpsteinWeek 6 2026 laat zien hoe politiek, media en recht steeds verder losraken van de realiteit.Jeroen en Willem bespreken de Epstein-files en wat er vooral níet wordt besproken.De nieuwe coalitie krijgt vorm, terwijl de oppositie vooral een decorfunctie lijkt te hebben.Het is koud en nat, maar klimaatmaatregelen worden onverminderd doorgedrukt.De rekening loopt op, tot de laatste cent is afgetroggeld.Binnen de EU stapelen de signalen zich op dat verkiezingen in meerdere lidstaten zijn gemanipuleerd.Kiezen lijkt steeds meer een ritueel zonder consequenties.De oorlog tegen vrije informatie escaleert verder.Dissidente geluiden worden actief bestreden en big tech komt onder zware politieke druk te staan.Spanje profileert zich openlijk als koploper van Agenda 2030.Duitsland ontvouwt plannen die wijzen op een toekomstige confrontatie met Rusland.Juridisch gebeurt er veel, maar recht lijkt steeds vaker afwezig.Nieuwe claims stellen dat mRNA-injecties jaren na toediening nog meetbaar zijn in menselijk weefsel.Deze video is geproduceerd door Café Weltschmerz. Café Weltschmerz gelooft in de kracht van het gesprek en zendt interviews uit over actuele maatschappelijke thema's. Wij bieden een hoogwaardig alternatief voor de mainstream media. Café Weltschmerz is onafhankelijk en niet verbonden aan politieke, religieuze of commerciële partijen.Wil je meer video's bekijken en op de hoogte blijven via onze nieuwsbrief? Ga dan naar: https://www.cafeweltschmerz.nl/videos/Wil je op de hoogte worden gebracht van onze nieuwe video's? Klik dan op deze link: https://bit.ly/3XweTO0

Vakcíny proti covidu na bázi mRNA výrazně zvyšují dobu přežití u pacientů s nádory plic anebo kůže v pokročilé fázi. Vědci z Floridské univerzity zjistili, že jejich podání stimuluje imunitní systém a tím přispívá k úspěšnosti onkologické léčby.Všechny díly podcastu Laboratoř můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand Therapeutics. Since the mRNA vaccine breakthroughs of the COVID-19 era, attention has turned to what's next for programmable medicines. While first- generation mRNA prove the power of transient genetic instruction, its instability, immune reactivity, and short-lived expression have limited its use mainly to vaccines. Emerging platforms like circular and logic circuit RNA are expanding the field's therapeutic horizons.HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsErik Digman Wiklund⁠, CEO, CircioJacob Becraft, Co-founder and CEO, Strand TherapeuticsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Looking 4 Healing Radio with Dr. Angelina Farella – Donio's concerns weren't unfounded speculation. As someone who worked directly with similar technologies in laboratory settings, he recognized the mRNA vaccines as gene therapy—a technology initially developed for cancer treatment and rare diseases. His research revealed that early clinical trials of modified mRNA therapeutics encountered...

Looking 4 Healing Radio with Dr. Angelina Farella – Donio's concerns weren't unfounded speculation. As someone who worked directly with similar technologies in laboratory settings, he recognized the mRNA vaccines as gene therapy—a technology initially developed for cancer treatment and rare diseases. His research revealed that early clinical trials of modified mRNA therapeutics encountered...

Bill and Hillary Clinton have agreed to testify before a congressional committee regarding their past ties to Jeffrey Epstein, a move that could spare the couple from possible prison time; The renewed five-day search for fugitive Dezi Freeman has entered its second day in Victoria’s Mount Buffalo National Park, with investigators now shifting their primary focus to the recovery of remains; Australia is launching a world-first clinical trial using mRNA technology to treat children battling aggressive and advanced brain tumours; The Amazon-backed documentary Melania has struggled significantly at the Australian box office, debuting in 33rd place with just over $22,000 in opening weekend ticket sales. THE END BITS Support independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Host: Gemma DonahoeAudio Producer: Lu HillBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

The latest episode of Tin Foil Hat features Justin Leslie discussing his work on Pfizer's mRNA vaccine platform, why he became a whistleblower, and his views on true health, the terrain model, and virology. He shares insider perspectives on Project Veritas, Project Whistleblower, and investigations into alternative media figures, raising questions about transparency and controlled opposition. The episode also explores media manipulation, medical ethics, bodily autonomy, and alternative health models beyond Big Pharma. Please subscribe to the new Tin Foil Hat youtube channel:  https://www.youtube.com/@TinFoilHatYoutube Grab your copy of the 2nd issue of the Chaos Twins now and join the Army Of Chaos: https://bit.ly/415fDfY Check out Sam "DoomScrollin with Sam Tripoli and Midnight Mike" Every Tuesday At 4pm pst on Youtube, X Twitter, Rumble and Rokfin! Join the WolfPack at Wise Wolf Gold and Silver and start hedging your financial position by investing in precious metals now! Go to https://www.samtripoli.gold/ and use the promo code "TinFoil" and we thank Tony for supporting our show. CopyMyCrypto.com: The 'Copy my Crypto' membership site shows you the coins that the youtuber 'James McMahon' personally holds - and allows you to copy him. So if you'd like to join the 1300 members who copy James, then stop what you're doing and head over to: https://copymycrypto.com/tinfoilhat/ You'll not only find proof of everything I've said - but my listeners get full access for just $1 LiveLongerFormula.com: Check out https://www.livelongerformula.com/sam — Christian is a longevity author and functional health expert who helps you fix your gut, detox, boost testosterone, and sleep better so you can thrive, not just survive. Watch his free masterclass on the 7 Deadly Health Fads, and if it clicks, book a free Metabolic Function Assessment to get to the root of your health issues. Grab Tickets To Sam Tripoli's Live Shows At SamTripoli.com: Hollywood, CA: 2/10 Perryville, MD: 2/20 Pottstown, PA: 2/21 Las Vegas, NV: 2/28 Bakersfield, CA: 3/6 Yuma, AZ: 3/7 Hollywood, CA: 3/10 Batavia, IL: 3/26-3/28 Toronto, CA: 4/17-18 Dallas, TX: 4/24 Fort Worth, TX: 4/25 Albuquerque, NM: 6/12-6/13 Lawerence, KS: 9/17-9/19 Tulsa, OK: 10/9-10/10   Please check out Justin Leslie's internet:  Website: https://justintegrity.net Rumble: https://rumble.com/c/justintegrity Twitter: https://x.com/justintegrityy Instagram: https://www.instagram.com/justin.leslie3/ Youtube: https://www.youtube.com/@JustIntegrityNetwork   Please check out Sam Tripoli's internet: Linktree: https://linktr.ee/samtripoli Sam Tripoli's Stand Up Youtube Page: https://www.youtube.com/@SamTripoliComedy  Sam Tripoli's Comedy Instagram: https://www.instagram.com/samtripolicomedy/%20P Sam Tripoli's Podcast Clip Instagram: https://www.instagram.com/samtripolispodcastclips/   Please support our sponsors: ShipStation: Try ShipStation free for sixty days with Full access to all features, No credit card needed! Go to Ship Station dot com  and use code tinfoil for sixty  days for free! Sixty days gives you plenty of time to see exactly how much time and money you're saving on every shipment.That's Ship Station dot com code tinfoil. Ship Station dot com code tinfoil. QUO: Quo is the #1-rated business phone system on G2 with over 3,000 reviews, trusted by more than 90,000 businesses to stay connected and professional. Calls, texts, voicemails, transcripts, and contacts all live in one clean view, giving your team full context and faster communication. Make this the year no opportunity slips away. Try Quo for free and get 20% off your first six months at Quo dot com slash TINFOIL. That's Q-U-O dot com slash TINFOIL. Quo — no missed calls, no missed customers.  

On today's HighWire, Former CDC Director Robert Redfield is now saying the quiet part out loud, admitting we were right about mRNA and spike protein. Also, Del Celebrates RFK Jr.'s Announcement of 21 new members of the Interagency Autism Coordinating Committee (IACC), the committee responsible for coordinating the government's autism research and response. This is huge, and Del has the details.Then, we examine Moderna's announcement that it is halting new Phase 3 vaccine trials, citing reduced market incentives under increased federal oversight. What does this decision reveal about safety testing, accountability, and public health priorities?Also, a deep dive into the UK's newly announced AI surveillance system — described by officials as a “panopticon.” We unpack the origins of the term and what it signals about the future of mass surveillance.Plus, as fraud investigations rock Minnesota, autism education providers are facing devastating funding cuts. Jennifer Larson of Holland Center joins Del to explain how legitimate, long-standing programs are now at risk — and how families are paying the price.Guest: Jennifer LarsonBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

00:01:22:16 — Minnesota Raids and the Return of Ruby Ridge–Style Federal AbuseKnight opens by warning that federal law enforcement actions in Minnesota mirror Ruby Ridge–era abuses, revealing an escalation in federal violence. 00:02:38:03 — RICO Lawsuit Targets Pediatricians and the CDCKnight introduces a sweeping RICO case alleging coordinated fraud surrounding the childhood vaccine schedule involving the CDC, AAP, and pharmaceutical interests. 00:03:44:19 — RICO Statutes: From Organized Crime to Government AbuseKnight explains how anti-mafia laws evolved into tools for civil asset forfeiture and pre-punishment now used against the public. 00:06:36:00 — Forty Years of Missing Vaccine Safety DataKnight highlights allegations that legally required safety studies tied to the 1986 vaccine liability shield were never produced. 00:08:58:19 — Autoimmune Epidemics Linked to Immune System DisruptionKnight connects rising asthma, diabetes, and autoimmune disease rates to chronic immune dysregulation rather than natural causes. 00:10:54:05 — Trump Revives mRNA and AI Genetic ProgramsKnight warns that renewed efforts to merge AI with mRNA technology represent an expansion of transhumanist experimentation. 00:12:14:17 — Self-Amplifying mRNA and Military FundingKnight argues Pentagon-funded research into replicating genetic injections signals coercive deployment beyond informed consent. 00:16:56:20 — Republicans Treat Gun Ownership as Inherent SuspicionKnight criticizes GOP figures who frame lawful firearm possession as automatic danger, undermining the Second Amendment. 00:21:12:00 — Vehicle Kill Switches and the End of Freedom of MovementKnight and Kubiniec warn that mandated remote car shutoff technology threatens the practical right to travel. 01:02:30:19 — James Bovard Joins to Compare Minnesota Killing to Ruby RidgeKnight brings on James Bovard to analyze why the Minnesota killing echoes Ruby Ridge and Waco–era federal abuses. 01:08:19:09 — Pattern of Federal Cover-Ups: Lie, Exaggerate, JustifyBovard outlines a recurring federal pattern of suppressed evidence, exaggerated threats, and post-hoc rationalizations. 01:37:30:16 — Trump's Vision of Power Without Constitutional LimitsKnight closes by arguing Trump defines “greatness” as unchecked executive power rather than constitutional restraint. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Following a routine surgery in Washington, the mother of ‘Baby Alex' says her newborn died after doctors administered a blood transfusion – without parental consent – from someone vaccinated with the still-new mRNA COVID vaccine. His parents say the clot stretched from his knee to his heart. Tom Renz is an attorney, author, and political analyst. He served with Justice Tarun Chatterjee of the Supreme Court of India and was mentored by a Nuremberg prosecutor. Renz focuses on constitutional issues, medical freedom, and government accountability. Follow at https://x.com/RenzTom K-von is widely known as the most famous “half-Persian comedian” in the world. He has appeared on Dry Bar Comedy, Netflix, NBC's Last Comic Standing, and delivered a widely viewed TED Talk. He stars in the film Funny Thing About Love alongside Jon Heder and tours nationally. Learn more at https://k-voncomedy.com Clinton Ohlers PhD is Vice President and Director of Media Relations for SafeBlood Donation. He earned his PhD from the University of Pennsylvania and conducted research at the University of Hong Kong during the early COVID outbreak. He is co-authoring documented case studies on mRNA-related transfusion injuries. Learn more at https://safeblood.com⠀Devlyn Steele is the Director of Education at Augusta Precious Metals, which sponsors Ask Dr. Drew. He is Harvard-trained and specializes in explaining economic trends, currency dynamics, and the role of gold and silver in accessible terms for the public. Learn more about why Dr. Drew and Susan trust Augusta Precious Metals – and get the same educational resources for free – at https://drdrew.com/gold 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

00:01:22:16 — Minnesota Raids and the Return of Ruby Ridge–Style Federal AbuseKnight opens by warning that federal law enforcement actions in Minnesota mirror Ruby Ridge–era abuses, revealing an escalation in federal violence. 00:02:38:03 — RICO Lawsuit Targets Pediatricians and the CDCKnight introduces a sweeping RICO case alleging coordinated fraud surrounding the childhood vaccine schedule involving the CDC, AAP, and pharmaceutical interests. 00:03:44:19 — RICO Statutes: From Organized Crime to Government AbuseKnight explains how anti-mafia laws evolved into tools for civil asset forfeiture and pre-punishment now used against the public. 00:06:36:00 — Forty Years of Missing Vaccine Safety DataKnight highlights allegations that legally required safety studies tied to the 1986 vaccine liability shield were never produced. 00:08:58:19 — Autoimmune Epidemics Linked to Immune System DisruptionKnight connects rising asthma, diabetes, and autoimmune disease rates to chronic immune dysregulation rather than natural causes. 00:10:54:05 — Trump Revives mRNA and AI Genetic ProgramsKnight warns that renewed efforts to merge AI with mRNA technology represent an expansion of transhumanist experimentation. 00:12:14:17 — Self-Amplifying mRNA and Military FundingKnight argues Pentagon-funded research into replicating genetic injections signals coercive deployment beyond informed consent. 00:16:56:20 — Republicans Treat Gun Ownership as Inherent SuspicionKnight criticizes GOP figures who frame lawful firearm possession as automatic danger, undermining the Second Amendment. 00:21:12:00 — Vehicle Kill Switches and the End of Freedom of MovementKnight and Kubiniec warn that mandated remote car shutoff technology threatens the practical right to travel. 01:02:30:19 — James Bovard Joins to Compare Minnesota Killing to Ruby RidgeKnight brings on James Bovard to analyze why the Minnesota killing echoes Ruby Ridge and Waco–era federal abuses. 01:08:19:09 — Pattern of Federal Cover-Ups: Lie, Exaggerate, JustifyBovard outlines a recurring federal pattern of suppressed evidence, exaggerated threats, and post-hoc rationalizations. 01:37:30:16 — Trump's Vision of Power Without Constitutional LimitsKnight closes by arguing Trump defines “greatness” as unchecked executive power rather than constitutional restraint. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

My co-host Ken Suzan and I are welcoming you to episode 171 of our podcast IP Fridays! Today's interview guest is the president of the German Patent and Trademark Office Eva Schewior! But before we jump into this very interesting interview, I have news for you: The US Supreme Court has taken up an important patent law case concerning so-called “skinny labels” for generic drugs. Specifically, the highest US court is reviewing a case in which Amarin accuses generic drug manufacturer Hikma of inciting doctors to use the cholesterol drug Vascepa in violation of patents by providing a limited package insert. In two landmark decisions, the UPC Court of Appeal clarified the criteria for inventive step and essentially confirmed the EPO’s typical “problem-solution” approach (Amgen v Sanofi and Meril v Edwards). However, experts are not entirely sure whether the Court of Appeal’s decisions, particularly those relating to the determination of the closest prior art, deviate from EPO practice. As a result of Brexit, mutual recognition of trademark use between the EU and the UK will cease to apply from January 1, 2026. Use of a trademark only in the UK will then no longer count as use of an EU trademark for the purpose of maintaining rights – and conversely, EU use will no longer count for British trademarks. Bayer is attacking several mRNA vaccine manufacturers in the US (Pfizer, BioNTech, Moderna, and J&J separately). The core allegation: patent infringements relating to old (Monsanto) patents on mRNA stabilization; Bayer is seeking damages, not sales bans. DISCO Pharmaceuticals from Cologne signs an exclusive license agreement with Amgen (potentially up to USD 618 million plus royalties) for novel cancer therapies targeting surface structures. Relevant from an IP perspective: license scope, milestones, data/know-how allocation. And now let's jump into the interview with Eva Schewior! The German IP System in Transition: Key Insights from DPMA President Eva Schewior In an in-depth conversation on the IP Fridays podcast, Eva Schewior, President of the German Patent and Trademark Office (DPMA), outlined how Germany's IP system is responding to rising demand, technological change, and a fundamentally altered European patent landscape. The interview offers valuable insights for innovators, companies, and IP professionals navigating patent, trademark, and design protection in Europe. Sustained Demand and Procedural Efficiency Despite the introduction of the Unitary Patent system, national German IP rights continue to see strong and growing demand. According to Schewior, application numbers at the DPMA have been increasing for years, which she views as a strong vote of confidence in the quality and reliability of German IP rights. At the same time, this success creates pressure on examination capacity. The average duration of patent proceedings at the DPMA is currently around three years and two months from filing to grant, provided applicants request examination early and avoid extensions. Internationally, this timeframe remains competitive. Nevertheless, shortening procedures remains a strategic priority. Search requests alone have risen by almost 50% over the past decade, yet the DPMA still delivers search reports on time in around 90% of cases. To better reflect applicant needs, the DPMA distinguishes between two main user groups: applicants seeking a rapid grant, often as a basis for international filings, and applicants primarily interested in a fast, high-quality initial assessment through search or first examination. Future procedural adjustments are being considered to better serve both groups. The Role of Artificial Intelligence Artificial intelligence already plays a practical role at the DPMA, particularly in patent search, classification, and the translation of Asian patent literature. Schewior emphasized that the office is closely monitoring rapid developments in AI to assess where these tools can further improve efficiency. However, she made clear that AI will remain a supporting technology. In public administration, and especially in IP examination, final decisions must always be taken and reviewed by humans. AI is seen as a way to relieve examiners of routine tasks so they can focus on substantive examination and quality. Maintaining and Monitoring Examination Quality Quality assurance is a central pillar of the DPMA's work. Schewior reported consistently positive feedback from users, but stressed that maintaining quality is a continuous task. The office applies systematic double checks for grants and refusals and uses internal quality management tools to randomly review searches and first office actions during ongoing proceedings. External feedback is equally important. The DPMA's User Advisory Board, which includes patent attorneys, startups, and patent information centers, plays a key role in identifying issues and suggesting improvements. Several of its recommendations have already been implemented. Trademark Filings and Bad-Faith Applications The trademark side of the DPMA has experienced particularly strong growth. In 2025, the office received around 95,000 trademark applications, an increase of approximately 18% compared to the previous year. Much of this growth came from abroad, especially from China. While new trademark types such as sound marks, multimedia marks, and holograms have so far seen only moderate uptake, word marks and figurative marks remain dominant. A growing challenge, however, is the rise in bad-faith trademark filings. The DPMA has responded by intensively training examiners to identify and handle such cases. Procedural reforms following EU trademark law modernization have also shifted competencies. Applicants can now choose whether to bring revocation and invalidity actions before the courts or directly before the DPMA. While courts may act faster, proceedings before the DPMA involve significantly lower financial risk, as each party generally bears its own costs. Accelerated Examination as a Practical Tool Despite rising filing numbers, the DPMA aims to avoid significant delays in trademark proceedings. Organizational restructuring within the trademark department is intended to balance workloads across teams. Schewior highlighted the option of accelerated trademark examination, available for a relatively modest additional fee. In practice, this can lead to registration within a matter of weeks, without affecting priority, since the filing date remains decisive. New Protection for Geographical Indications A major recent development is the extension of EU-wide protection for geographical indications to craft and industrial products. Since late 2025, the DPMA acts as the national authority for German applications in this area. The first application has already been filed, notably for a traditional German product. Under the new system, applications undergo a national examination phase at the DPMA before being forwarded to the EUIPO for final decision. Products eligible for protection must originate from a specific region and derive their quality or reputation from that origin, with at least one production step taking place there. The EU estimates that around 40 German products may qualify. Outreach, SMEs, and Education Schewior underlined the DPMA's statutory duty to inform the public about IP rights, with a particular focus on small and medium-sized enterprises. The office has significantly expanded its presence on platforms such as LinkedIn and YouTube, offering accessible and practical IP content. Studies show that fewer than 10% of European SMEs use IP rights, despite evidence that IP-owning companies generate higher revenues. To address this gap, the DPMA is expanding outreach formats, strengthening cooperation with educational institutions, and publishing new empirical studies, including a forthcoming analysis of patenting behavior among innovative German startups conducted with WIPO. Strategic Challenges Ahead Looking forward, Schewior identified several key challenges: insufficient awareness of IP protection among SMEs and startups, a tendency in some sectors to rely solely on trade secrets, and the growing problem of product and trademark piracy linked to organized crime. From an institutional perspective, the DPMA must remain attractive and competitive in a European system offering multiple routes to protection. This requires legally robust decisions, efficient procedures, qualified staff, and continuous investment in IT and training. Careers at the DPMA Finally, Schewior highlighted recruitment as a strategic priority. The DPMA recently hired around 50 new patent examiners and continues to seek experts in fields such as electrical engineering, e-mobility, IT, and aerospace, as well as IT specialists, lawyers, and staff in many other functions. She emphasized the DPMA's role as Europe's largest national patent office and a globally significant, stable, and family-friendly employer at the forefront of technological development. German and European Patents as Complementary Options In her closing remarks, Schewior addressed the post-UPC patent landscape. Rather than competing, German and European patent systems complement each other. For many SMEs, a German patent alone may be sufficient, particularly where Germany is the core market. At the same time, the possibility of holding both a European patent and a national German patent offers strategic resilience, as national protection can survive even if a European patent is revoked. Her key message was clear: the range of options has never been broader, but making informed strategic choices is more important than ever. If you would like, I can also adapt this article for a specialist legal audience, condense it for a magazine format, or rework it as a thought-leadership piece for LinkedIn or your website. Rolf Claessen: Today's interview guest is Eva Schewior. If you don't know her yet, she is the President of the German Patent and Trademark Office. Thank you very much for being here. Eva Schewior: I'm very happy that you're having me today. Thank you, Mr. Claessen. Rolf Claessen: Shortening the length of procedures has been a stated goal since you took office. What is the current situation, and which measures are in place to achieve this goal? Eva Schewior: First of all, I'm very glad that German IP rights are in high demand. Even though applicants in Europe have multiple options today to obtain protection for their innovations, we have seen increasing application numbers for years at my office, even after the introduction of the Unitary Patent system. I see this as very positive feedback for our work. It is clear, however, that the high number of applications leads to a constantly increasing workload. At the same time, we want to remain attractive for our applicants. This means we must offer not only high-quality IP rights but also reasonable durations of proceedings. Ensuring this remains a central and permanent objective of our strategy. The average duration of proceedings from filing to grant is currently about three years and two months, provided that applicants file an examination request within the first four months after application and do not request extensions of time limits. In other cases, the average duration of proceedings is admittedly longer. With these three years and two months, we do not have to shy away from international comparison. Nonetheless, we strive to get better. In the last few years, we were able to improve the number of concluded proceedings or to keep them at a high level. In some areas, we were even able to shorten durations of proceedings a bit, though not yet to the extent that we would have wished for. Our efforts are often overtaken by the increasing demand for our services. Just to give you an example, in the last ten to fifteen years, search requests increased by nearly fifty percent. Despite this, we managed to deliver search reports in ninety percent of all cases in time, so that customers have enough time left to take a decision on a subsequent application. I have to admit that we are not equally successful with the first official communication containing the first results of our examination. Here, our applicants need a bit more patience due to longer durations of proceedings. But I think I do not have to explain to your expert audience that longer processing times depend on various reasons, which are in no way solely to be found on our side as an examination office. To further reduce the length of proceedings, we need targeted measures. To identify them, we have analyzed the needs of our applicants. It has been shown that there are two main interests in patent procedures. About three quarters of our applicants have a very strong interest in obtaining a patent. They mainly expect us to make fast decisions on their applications. Here we find applicants who want to have their invention protected within Germany but often also wish for subsequent protection outside Germany. The remaining quarter consists of applicants that are solely interested in a fast and high-quality first assessment of the application by means of a search or a first official examination. We observe that these applicants use our services before they subsequently apply outside Germany. This latter group has little interest in continuing the procedure before my office here in Germany. We are currently considering how we can act in the best interest of both groups. What I can certainly say is that we will continue to address this topic. And of course, in general, it can be said that if we want to shorten the duration of proceedings, we need motivated and highly skilled patent examiners. Therefore, we are currently recruiting many young colleagues for our offices in Munich and Jena, and we want to make our procedures more efficient by using new technical options, thus taking workload from patent examiners and enabling them to concentrate on their core tasks and on speedy examination. Rolf Claessen: Thank you very much. I also feel that the German Patent and Trademark Office has become quite popular, especially with the start of the UPC. Some applicants seem to find that it is a very clever option to also file national patents in Germany. Eva Schewior: I think you're perfectly right, and I think we will come to this point later. Rolf Claessen: In 2023, you mentioned artificial intelligence as an important tool for supporting patent examiners. What has happened regarding AI since then? Eva Schewior: Of course, we are already successfully using AI at our office. For instance, in the field of patent search, we use AI-based tools that make our examiners' work easier. We also use AI quite successfully for classification and for the translation of Asian patent literature into English. In the meantime, we have seen a rapid development of AI in the market. I think it is strategically imperative to get an overview and to make realistic assessments of what AI is capable of doing to make our procedures more efficient. Therefore, we are observing the market to find out where AI can perform tasks so that we enable examiners to concentrate on their core business. There are many ideas right now in our office where artificial intelligence can help us tackle challenges, for instance demographic change, which certainly also affects our office, and maintaining our quality standards. We will strategically promote new tools in this field to cope with these challenges. But this much is also clear: humans will always stay in our focus. Especially in public administration, I consider it a fundamental principle that in the end, decisions must be taken and reviewed by humans. AI may help us reach our goals in a more efficient way, but it can never replace patent or trademark examiners. Rolf Claessen: You have made quality improvements in patent examination a priority and have already implemented a number of measures. How would you describe the current situation? Eva Schewior: I often receive positive feedback from different sides that our users are very satisfied with the quality of our examination, and I'm very glad about that. But maintaining this quality standard is a permanent task, and we must not become careless here. For years, for instance, we have established double checks for all grants and rejections. In addition, we have introduced a quality management tool that enables us, even during the examination process, to randomly check the quality of first office communications and searches. This helps us detect critical trends and take appropriate countermeasures at a very early stage. What is also very important when it comes to patent quality is to actively ask our customers for their feedback. We do this in different ways. Just to give you an example, we have a User Advisory Board, which is a panel of external experts implemented a couple of years ago. Discussing questions of quality is regularly on the agenda of this board. We carefully listen to criticism, ideas, and suggestions, and we have already implemented some of them for the benefit of the office and our users. Rolf Claessen: The German Patent and Trademark Office, as the largest patent and trademark office in Europe, records very high numbers of trademark applications. What are you currently especially concerned with in the trademark area? Eva Schewior: In 2025, we saw around ninety-five thousand trademark applications. This is an increase of eighteen percent compared to the previous year, and I have to say that this took us by surprise. Especially applications from outside Germany, and above all from China, have risen significantly. It is of course challenging to cope with such a sudden increase on an organizational level. Another challenge is dealing with trademark applications filed in bad faith, which we are currently seeing more and more of. We have thoroughly trained our trademark examiners on how to identify and handle such applications. As regards the new types of trademarks, the rush has been moderate so far. Sound marks, multimedia marks, or holograms are apparently not yet common solutions for the majority of applicants. The key focus remains on word marks and combined word and figurative marks. Nevertheless, I believe that the new trademark types are a meaningful supplement and may play a greater role as digitization advances. The most significant changes, however, concern procedures. Applicants can now choose whether to file revocation or invalidity actions with the courts or with our office. While courts may proceed somewhat faster, the financial risk is higher. Before the DPMA, each party generally bears its own costs, apart from exceptional cases. Rolf Claessen: How does this dynamic filing development impact the duration of trademark proceedings? Eva Schewior: This is indeed a major organizational challenge. For a long time, our trademark department managed to keep durations of proceedings very short, especially with regard to registration. Despite the recent increases in applications, especially in 2025, we hope to avoid a significant extension of processing times. We have restructured the organization of the trademark department to distribute applications more equally among teams. Applicants should also be aware that it is possible to request accelerated examination for a relatively moderate fee of two hundred euros. This often leads to registration within a very short time. The filing date, of course, always determines priority. Rolf Claessen: Since December 2025, the EU grants protection not only for agricultural products but also for craft and industrial products through geographical indications. Has your office already received applications? Eva Schewior: Yes, we have received our first application, and interestingly it concerns garden gnomes. Protected geographical indications are an important topic because they help maintain traditional know-how in regions and secure local jobs. The DPMA is the competent authority for Germany. Applications go through a national examination phase at our office before being forwarded to the EUIPO, which takes the final decision on EU-wide registration. Eligible products must originate from a specific region and derive their quality, reputation, or characteristics from that origin, with at least one production step taking place there. Rolf Claessen: The DPMA has expanded its outreach activities, including social media. What else is planned? Eva Schewior: Raising awareness of IP rights, especially among small and medium-sized enterprises, is part of our statutory duty. We currently use LinkedIn and YouTube to communicate IP topics in an understandable and engaging way. We also plan dedicated LinkedIn channels, for example for SMEs. Studies show that fewer than ten percent of European SMEs use IP rights, even though those that do earn significantly more on average. In 2026, we will further expand outreach activities, cooperate more closely with universities and educational institutions, and publish new studies, including one on the patenting behavior of innovative German start-ups conducted together with WIPO. Rolf Claessen: Where do you see the biggest future challenges in IP? Eva Schewior: Germany depends on innovation, but awareness of IP protection is still insufficient, particularly among SMEs and start-ups. Some companies deliberately avoid IP rights and rely on trade secrets, which I consider risky. Another growing concern is the increase in product and trademark piracy, often linked to organized crime. For our office, remaining attractive and competitive is crucial. Applicants have many options in Europe, so we need fast procedures, legally robust decisions, qualified staff, and modern IT systems. Rolf Claessen: The DPMA is currently recruiting. Which areas are you focusing on? Eva Schewior: Our focus is on patent examination and IT. We recently hired fifty new patent examiners and are particularly looking for experts in fields such as electrical engineering, e-mobility, IT, and aerospace. We are Europe's largest national patent office and offer meaningful, secure jobs with fair compensation and strong development opportunities. Rolf Claessen: Is there a final message you would like to share with our listeners? Eva Schewior: The Unitary Patent system has created many new options. German and European patent systems do not compete; they complement each other. For many SMEs, a German patent may already be sufficient, especially where Germany is the core market. Holding both European and national patents can also be a strategic advantage. My key message is: be aware of the options, stay informed, and choose your IP strategy deliberately. Rolf Claessen: Thank you very much for being on IP Fridays. Eva Schewior: Thank you for having me. It was a pleasure.

20 Minutes of Shorts. The Re-Migration Act, Long COVID Symptoms are Actually Vaccine Injuries, Julie Kelly J6 Prosecutions, COVID Vax- Billions of Brains Injured, College Grads Unemployed   21 million Americans went to college and still earn less than $20 an hour. The proposed Re-Migration Act to revoke Citizenship since 1965 If citizenship was obtained through false statements, omissions, visa fraud, welfare fraud, or concealed criminal history. Professor Sucharit Bhakdi on COVID Vax- "We're seeing billions of people whose brains are not working anymore." Long COVID symptoms—exhaustion, brain fog, insomnia, fatigue—are actually vaccine injuries. FEMINISM WAS CREATED TO END CHRISTIANITY? JULIE KELLY J6 Long COVID symptoms—exhaustion, brain fog, insomnia, fatigue—are actually vaccine injuries.   Post Peter St Onge, Ph.D. @profstonge 21 million Americans went to college and still earn less than $20 an hour. College grads now make up a record 25% of unemployed. And their unemployment rate is now higher than high school grads. College degrees ain't what they used to be.   Post Andrew Branca Show @TheBrancaShow This isn't radical—it's black-letter immigration law being restated. The proposed Re-Migration Act of 2025/2026 (H.R. ___) amends the Immigration and Nationality Act to require DHS and USCIS to review naturalizations issued since 1965 for fraud, criminal concealment, or ineligibility. The legal standard is simple: preponderance of the evidence (51%). If citizenship was obtained through false statements, omissions, visa fraud, welfare fraud, or concealed criminal history, it can be revoked—because fraud voids consent ab initio. That principle has existed for decades. Naturalization is not magic. It is a conditional legal status dependent on truthful disclosure and lawful conduct. If someone lied at the visa stage, lied at the green-card stage, or lied at naturalization, the chain collapses—and denaturalization follows as a matter of law. That's not punishment. It's correction of fraud.   FEMINISM WAS CREATED TO END CHRISTIANITY? “The dragon, I really think, is feminism.” - Author Carrie Gress explains that until we get to the heart of what's feeding abortion, which is she says is “really feminism” we're not going to be able to not going to be able to end it. JackoWilliams64 @JackoWilliams64 JackoWilliams64 reposted Real America's Voice (RAV) @RealAmVoice @Bannons_WarRoom   JULIE KELLY: The Biden DOJ did not want to give full access to security footage from J6 because it would have shown the truth! This is why Parler was shut down! It was FILLED with clips of what police did to protestors that day. JackoWilliams64 reposted Bannon's WarRoom @Bannons_WarRoom @julie_kelly2   Professor Sucharit Bhakdi: "I am no longer optimistic anymore. And the reason is very simple." "I'm afraid that these mRNA vaccines have already done their job." "We're seeing billions of people whose brains are not working anymore." Post healthbot @thehealthb0t   Everything the media told you about Long COVID is a lie. COVID Vaccines alter T-Cells, causing VAIDS. Yale study on “post-vaccination syndrome” reveals Long COVID symptoms—exhaustion, brain fog, insomnia, fatigue—are actually vaccine injuries. Post Dr. Dawn Michael @DawnsMission

Dr. Jessica Rose, PhD, MSc, BSc, is a Senior Fellow specializing in Computational Biology from Canada. She holds a Bachelor's Degree in applied mathematics and a master's degree in Immunology from Memorial University of Newfoundland, and a PhD in Computational Biology from Bar Ilan University. Dr. Rose has completed two post-doctoral degrees in Molecular Biology from the Hebrew University of Jerusalem, and in Biochemistry from the Technion Institute of Technology. She is best known for her contributions to public health and safety related to the COVID-19 injectable products, and her analyses of pharmacovigilance databases like VAERS. In this episode, Drs. Brian and Jessica talk about… (00:00) Intro (04:57) Dr. Jessica's upbringing, personality, and scientific pursuits (09:41) Covid vaccines, natural immunity, and bodily autonomy of individuals (19:50) The research of Kevin McKernan on DNA in vials of COVID-19 vaccines (27:39) The composition and production of Covid mRNA vaccines (33:04) National health regulation agencies and Covid vaccine DNA contamination (35:54) Lipid nanoparticles in mRNA vaccines and how they impact human health (44:22) Vaccine injuries due to spike protein proliferation and how the spike protein ruins the human immune system (54:38) Spike protein detox therapies (01:01:12) Fascia release (01:03:07) Cholesterol, gal bladder health, and nutrition (01:07:54) Fasting, autophogy, and the microbiome (01:11:33) Peer review and post-peer review attacks on valid research (01:21:53) Outro   For more information, please see the links below. Thank you for listening!   Links:   Resources Mentioned in this Episode: Jules Horn (Fascia Release): https://www.youtube.com/@Jules_horn Science Guardians (post-peer review group): https://x.com/SciGuardians   Dr. Jessica Rose: Research: https://www.researchgate.net/profile/Jessica-Rose-24 Why does DNA remain in vials of COVID-19 mRNA Shots?: https://rumble.com/v74rdvs-why-does-dna-remain-in-vials-of-covid-19-mrna-shots.html What Jessica Rose Knows: Dr. Jessica Rose on DarkHorse: https://rumble.com/v5q0zl8-what-jessica-rose-knows-dr.-jessica-rose-on-darkhorse.html   Dr. Brian Lenzkes:  Arizona Metabolic Health: https://arizonametabolichealth.com/ Low Carb MD Podcast: https://www.lowcarbmd.com/   HLTH Code: HLTH Code Promo Code: METHEALTH • • HLTH Code Website: https://gethlth.com

James Gallagher stands by four lanes of traffic and inhales exhaust fumes all to see if he can see air pollution in his body. He looks at an intriguing finding that an mRNA vaccine might benefit people being treated with immunotherapy for some cancers and could we be on the cusp of a holy grail in dentistry? A breakthrough could mean we will soon be able to replace the enamel on our teeth. Presenter: James Gallagher Producer: Tom Bonnett Researcher: Thom Hunt Editor: Ilan Goodman

Protect Your Retirement with a PHYSICAL Gold and/or Silver IRA https://www.sgtreportgold.com/ CALL( 877) 646-5347 - You Can Trust Noble Gold   Join us for this incredible roundtable exposé with Jesse Beltran, Martt Hazen and Sarah Westall as we reveal the TRUTH about the ongoing WAR against humanity. We have the receipts, even those who didn't take the "vaccine" are transfected, and we all have more in common with those suffering from 'Havana Syndrome' than you know. But the good news it, there are real world remedies to the great culling. Thanks for tuning in.   Remove heavy metals, graphene oxide & nanotech from your blood w/ MaterPeace: https://masterpeacebyhcs.com/?ref=4094   Jesse Beltran's site: https://www.cosmicclarityconnections.org/   Sarah Westall: https://sarahwestall.com/ https://rumble.com/embed/v72jf0y/?pub=2peuz

A typical vaccine stimulates a person's immune system, yet only a portion of the immune response actually targets the disease it's designed to protect against. However, a new technology may be changing that dynamic.In this episode, I sit down with Lou Reese, an entrepreneur who has led or co-founded several biotech companies and has been working on synthetic peptide-based active immunotherapy medicines. He's co-CEO of United Biomedical and co-founder of Vaxxinity, Cana Life, and Axxium.He's working on a product that could—if proven successful—transform our approach to treating and preventing Alzheimer's. He and his team also have a product that has shown preliminary promise in phase 1 trials in treating Parkinson's.In this episode, he also reveals an incredible story: He and his team previously developed a peptide-based active immunotherapy vaccine candidate for COVID-19, and they successfully completed Phase 1 and Phase 2 trials. Institutional backing, however, favored Pfizer and Moderna. In 2022, Lou Reese's team was invited to the White House “Summit on the Future of COVID‑19 Vaccines,” where they presented their candidate as an alternative to Pfizer's mRNA vaccine, which by then had been associated with serious side effects.In the end, their product was never approved, and related content on YouTube was marked as misinformation.Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comFind out how the future of AI could impact your retirement during Zach Abraham's free “New Year Reset” live webinar January 29th 3:30pm Pacific. Register at KnowYourRiskPodcast.com.Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeYou wouldn't believe the excuse a judge has used to allow pharma to continue to harm your kids...Episode Links:Aaron Siri: "They reported two children died of measles in Texas recently. We represent one of those families. That child did not die of measles. We have all the medical records… The other child we don't represent but… that also wasn't measles."“The judge said the American Academy of Pediatrics can sue RFK Jr. to block the revised vaccine schedule because its members will have to talk more about vaccines with patients, harming their financial interests.”Doctors STILL telling patients: "You're NOT vaccine injured!"  Former CDC Director Dr. Robert Redfield: "We don't have a lot of honesty about vaccine injury. I spend my clinical time on long COVID patients with vaccine injury from the mRNA vaccines."WATCH: Peter Hotez tells woman her repeated COVID infections are basically her fault for skipping boosters.Bill Maher Delivers a Brutal Message to the COVID “Experts” Who Got It Wrong

Dr. Peter McCullough is a cardiologist, internist, and epidemiologist with decades of experience in cardiovascular medicine and clinical research. He is widely published and has been a prominent, outspoken voice during the COVID-19 pandemic, focusing on early treatment strategies, vaccine safety, and critical analysis of public health data. Dr. McCullough is known for challenging prevailing narratives and advocating for rigorous scientific debate and medical transparency.   In this episode, Drs. Brian and Peter talk about… (00:00) Intro (04:44) The true risk of Covid Vaccine injury due to the spike protein (10:17) Why the the proliferation of the spike protein in the human body is so dangerous (13:08) Why the spike protein vaccine idea did not work to prevent Covid (14:55) Why annual vaccine booster shots is ineffective (16:52) Concerns about mRNA vaccines and the human genome (19:28) Spike protein detoxification for people who have received a Covid mRNA vaccine (31:12) Why the idea that the spike protein could be causing health issues is largely ignored by medical professionals (34:31) Treating patients with high spike protein antibodies (38:19) The great cocaine epidemic, the great smoking epidemic, and how they relate to the current vaccine injury issue (43:47) When to start worrying about spike protein antibodies in your system (49:08) Spike proteins, heavy metals, mold, and Lyme disease (53:15) Outro   For more information, please see the links below. Thank you for listening!   Links:   Dr. Peter McCullough: X: https://x.com/P_McCulloughMD McCullough Foundation: https://mcculloughfnd.org Website: https://www.petermcculloughmd.com America Out Loud (podcast): https://www.americaoutloud.news/category/podcasts/the-mccullough-report/ Focal Points (Substack): https://sidestack.io/directory/substack/petermcculloughmd   Dr. Brian Lenzkes:  Arizona Metabolic Health: https://arizonametabolichealth.com/ Low Carb MD Podcast: https://www.lowcarbmd.com/   HLTH Code: HLTH Code Promo Code: METHEALTH • • HLTH Code Website: https://gethlth.com